SG Americas Securities LLC Has $227,000 Position in Global Blood Therapeutics, Inc. (GBT)

SG Americas Securities LLC increased its position in shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 93.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,288 shares of the company’s stock after acquiring an additional 4,014 shares during the period. SG Americas Securities LLC’s holdings in Global Blood Therapeutics were worth $227,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. State of Wisconsin Investment Board bought a new stake in Global Blood Therapeutics during the 2nd quarter worth approximately $766,000. Rhumbline Advisers increased its holdings in Global Blood Therapeutics by 118.5% during the 2nd quarter. Rhumbline Advisers now owns 41,801 shares of the company’s stock worth $1,143,000 after acquiring an additional 22,670 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in Global Blood Therapeutics during the 2nd quarter worth approximately $211,000. Schwab Charles Investment Management Inc. increased its holdings in Global Blood Therapeutics by 35.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 149,634 shares of the company’s stock worth $4,093,000 after acquiring an additional 38,829 shares during the period. Finally, Candriam Luxembourg S.C.A. increased its holdings in Global Blood Therapeutics by 7.8% during the 2nd quarter. Candriam Luxembourg S.C.A. now owns 83,000 shares of the company’s stock worth $2,270,000 after acquiring an additional 6,000 shares during the period. 86.07% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.chaffeybreeze.com/2017/09/19/sg-americas-securities-llc-has-227000-position-in-global-blood-therapeutics-inc-gbt.html.

In other news, insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $30.00, for a total transaction of $90,000.00. Following the sale, the insider now owns 141,655 shares in the company, valued at $4,249,650. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Deval L. Patrick sold 27,053 shares of Global Blood Therapeutics stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $29.69, for a total transaction of $803,203.57. Following the sale, the director now owns 12,053 shares in the company, valued at approximately $357,853.57. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,053 shares of company stock worth $983,204. Company insiders own 5.30% of the company’s stock.

A number of research firms recently weighed in on GBT. BidaskClub lowered shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Cowen and Company reaffirmed an “outperform” rating and set a $83.00 target price on shares of Global Blood Therapeutics in a report on Monday, August 14th. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $46.00 target price (up previously from $44.00) on shares of Global Blood Therapeutics in a report on Tuesday, August 8th. Wedbush reaffirmed an “ourperform” rating and set a $73.00 target price on shares of Global Blood Therapeutics in a report on Monday. Finally, ValuEngine raised shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 10th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $49.73.

Global Blood Therapeutics, Inc. (GBT) opened at 27.80 on Tuesday. The stock’s market cap is $1.21 billion. The firm has a 50-day moving average of $27.80 and a 200-day moving average of $30.05. Global Blood Therapeutics, Inc. has a 1-year low of $13.35 and a 1-year high of $41.15.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings data on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.06. During the same quarter in the prior year, the firm posted ($0.58) EPS. Analysts expect that Global Blood Therapeutics, Inc. will post ($2.45) EPS for the current fiscal year.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply